Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study
Name: Daclatasvir+ Asunaprevir
Description: HCV clearance and complete regression of NHL by ASV+ DCVType: DrugDaclatasvir + Asunaprevir
Description: patients who had undetectable HCV RNA levels at or after week 4. Viral relapse was defined as confirmed detectable HCV RNA levels during the post-treatment follow-up period in patients who had had undetectable HCV RNA levels at the end of treatment
Measure: HCV clearance and complete regression of NHL by ASV+ DCV Time: 2yearsCohort
There are 2 SNPs
An HCV RNA level of 105 IU per milliliter or higher 5. Being diagnosed to be low grade B cell non-Hodgkin lymphoma Exclusion Criteria: 1. Patients with hepatitis B virus infection, 2. Other liver diseases 3. HIV infection, 4. Pre-existing HCV variants in the NS5A domain included Q30R, L31 M/V, and Y93C/N 5. Evidence of cirrhosis, as documented by means of either liver biopsy or assessment of imaging results. --- Q30R ---
An HCV RNA level of 105 IU per milliliter or higher 5. Being diagnosed to be low grade B cell non-Hodgkin lymphoma Exclusion Criteria: 1. Patients with hepatitis B virus infection, 2. Other liver diseases 3. HIV infection, 4. Pre-existing HCV variants in the NS5A domain included Q30R, L31 M/V, and Y93C/N 5. Evidence of cirrhosis, as documented by means of either liver biopsy or assessment of imaging results. --- Q30R --- --- Y93C ---